KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
← catalyst calendarNCT06026410 · readout ≤ 165 d
Sponsored by Kura Oncology, Inc. (industry) · KURA — their whole pipeline →. With Mirati Therapeutics Inc..
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
300estimated
Sites
38
Countries
France, Germany, Italy +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-18 | actual | When the study began enrolling |
| Primary completion | Jan 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Solid Tumors With HRAS Alterations
- Non Small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Clear Cell Renal Cell Carcinoma (ccRCC)
- Renal Cell Carcinoma (Kidney Cancer)
- Non Clear Cell Renal Cell Carcinoma (nccRCC)
Interventions
- Drug: Darlifarnib — also filed as KO-2806
- Drug: Cabozantinib — also filed as Cabometyx
- Drug: Adagrasib — also filed as Krazati
Primary outcomes
what the primary-completion date above is the date OFRate of dose-limiting toxicities (DLTs)
measured DLTs will be evaluated during the first 28 days of KO-2806 treatment (dose escalation)
Descriptive statistics of adverse events (AEs)
measured First dose of KO-2806 up to and including 28 days after last dose of KO-2806 (dose escalation)
Incidence of dose interruptions, reductions, and discontinuations due to AE
measured First dose of KO-2806 up to last dose of KO-2806 or up to 24 months of treatment (dose escalation)
Objective Response Rate (ORR)
measured Up to an estimated period of 24 months (dose expansion)
Permalink · KURA's whole pipeline · Catalyst calendar · Every registered study · What changed